Financial Snapshot

Revenue
$16.15M
TTM
Gross Margin
97.06%
TTM
Net Earnings
-$57.40M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
732.62%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$153.7M
Q3 2024
Cash
Q3 2024
P/E
-1.865
Nov 29, 2024 EST
Free Cash Flow
-$53.87M
TTM

Revenues

Revenues

Revenue YoY Change

No data

Revenues

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019
Selling, General & Admin $32.31M $37.35M $18.66M $3.846M $1.655M
YoY Change -13.5% 100.14% 385.26% 132.39%
% of Gross Profit
Research & Development $49.59M $86.13M $51.05M $9.048M $1.224M
YoY Change -42.43% 68.7% 464.26% 639.22%
% of Gross Profit
Depreciation & Amortization $1.927M $700.0K $600.0K $500.0K $0.00
YoY Change 175.29% 16.67% 20.0%
% of Gross Profit
Operating Expenses $82.20M $123.5M $69.72M $12.89M $2.879M
YoY Change -33.43% 77.12% 440.69% 347.86%
Operating Profit -$82.20M -$123.5M -$69.72M -$12.89M
YoY Change -33.43% 77.12% 440.69%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019
Interest Expense $1.842M $2.764M -$6.439M $66.00K $107.0K
YoY Change -33.36% -142.93% -9856.06% -38.32%
% of Operating Profit
Other Income/Expense, Net $8.406M $2.764M -$6.027M $66.00K
YoY Change 204.12% -145.86% -9231.82%

Income/Loss

Pretax Income

Income Tax

No data

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

No data

Pretax & Net Income

Concept 2023 2022 2021 2020 2019
Pretax Income -$73.79M -$120.7M -$75.98M -$12.83M -$2.772M
YoY Change -38.87% 58.89% 492.26% 362.77%
Income Tax
% Of Pretax Income
Net Earnings -$73.79M -$120.7M -$75.98M -$12.83M -$2.772M
YoY Change -38.87% 58.89% 492.26% 362.77%
Net Earnings / Revenue
Basic Earnings Per Share -$1.85 -$3.65 -$8.95
Diluted Earnings Per Share -$1.85 -$3.65 -$2.358M -$391.9K -$84.68K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

No data

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

No data

Assets & Liabilities

Concept 2023 2022 2021 2020 2019
Cash & Short-Term Investments $119.3M $179.3M $274.7M $8.080M $19.69M
YoY Change -33.46% -34.74% 3300.19% -58.96%
Cash & Equivalents
Short-Term Investments $109.6M
Other Short-Term Assets $5.285M $6.721M $3.938M $23.00K $11.00K
YoY Change -21.37% 70.67% 17021.74% 109.09%
Inventory
Prepaid Expenses
Receivables $21.00K $598.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $124.6M $186.6M $278.7M $8.103M $19.70M
YoY Change -33.23% -33.04% 3339.13% -58.87%
Property, Plant & Equipment $24.81M $24.77M $1.239M $1.939M $76.00K
YoY Change 0.19% 1898.95% -36.1% 2451.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $109.0K $109.0K $30.00K
YoY Change -100.0% 0.0% 263.33%
Total Long-Term Assets $49.12M $24.77M $1.348M $2.048M $106.0K
YoY Change 98.34% 1737.31% -34.18% 1832.08%
Total Assets $173.7M $211.4M $280.0M $10.15M $19.81M
YoY Change
Accounts Payable $3.896M $7.097M $11.95M $1.077M $491.0K
YoY Change -45.1% -40.62% 1009.66% 119.35%
Accrued Expenses $13.85M $23.45M $6.491M $1.617M $116.0K
YoY Change -40.94% 261.21% 301.42% 1293.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.76M $31.63M $18.71M $3.689M $733.0K
YoY Change -18.57% 69.09% 407.13% 403.27%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.10M $18.92M $0.00 $165.0K $6.000K
YoY Change 6.23% -100.0% 2650.0%
Total Long-Term Liabilities $20.10M $18.92M $0.00 $165.0K $6.000K
YoY Change 6.23% -100.0% 2650.0%
Total Liabilities $48.02M $50.56M $18.71M $3.854M $739.0K
YoY Change -5.01% 170.23% 385.42% 421.52%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019
Basic Shares Outstanding 39.90M 33.03M 8.493M
Diluted Shares Outstanding 39.90M 33.03M 8.493M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

No data

Dividends

Dividends

No data

Stock Price

Market Cap: $107.04 Million

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 54 full-time employees. The company went IPO on 2021-10-08. The firm is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Industry: Pharmaceutical Preparations Peers: X4 Pharmaceuticals, Inc Zeo ScientifiX, Inc. Bolt Biotherapeutics, Inc. CURIS INC Senti Biosciences, Inc. Korro Bio, Inc. IMMUCELL CORP /DE/ SYNLOGIC, INC. SQZ Biotechnologies Co